Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "SSI"

5511 News Found

One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
Clinical Trials | December 30, 2025

One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty

The study met its primary endpoint with flying colors


Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
News | December 30, 2025

Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan

The partnership also sets the stage for broader collaboration on rare disease treatments


INOVIO’s DNA therapy for rare throat disease gets FDA review
Biotech | December 30, 2025

INOVIO’s DNA therapy for rare throat disease gets FDA review

INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway


Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours
Clinical Trials | December 30, 2025

Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours

CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development


Next Gen Diagnostics to spin off infection prevention unit
News | December 29, 2025

Next Gen Diagnostics to spin off infection prevention unit

NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection


ENHERTU gains first-ever nod in China for metastatic breast cancer
Drug Approval | December 29, 2025

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy


Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Clinical Trials | December 29, 2025

Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial

Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis


SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
Clinical Trials | December 29, 2025

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38


WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure
Sustainability | December 29, 2025

WuXi Biologics wins HERA 2025 Award for outstanding ESG disclosure

The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide


CPHI & PMEC India 2025 ignites pharma innovation and partnerships
News | December 29, 2025

CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows